Reasons that prevent the inclusion of Alzheimer's disease patients in clinical trials. (15th March 2013)

• Record Type: Journal Article
• Authors: Rollin‐Sillaire, Adeline; Breuilh, Laetitia; Salleron, Julia; Bombois, Stéphanie; Cassagnaud, Pascaline; Deramecourt, Vincent; Mackowiak, Marie‐Anne; Pasquier, Florence
• Is Part Of: British journal of clinical pharmacology. Volume 75:Number 4(2013:Apr.)
• Page Start: 1089
• Page End: 1097
• Publication Date: 2013-03-15
• Subjects: Pharmacology -- Periodicals; Drugs -- Periodicals; 615.1
• DOI: 10.1111/j.1365-2125.2012.04423.x
• Languages: English
• ISSNs: 0306-5251

Abstract

<abstract abstract-type="main"> <title> <x xml:space="preserve">Abstract</x> </title> <sec id="bcp4423-sec-0001" sec-type="section"> <title>Aim</title> <p>To assess reasons that prevent Alzheimer's disease (AD) patients from being included in clinical trials.</p> </sec> <sec id="bcp4423-sec-0002" sec-type="section"> <title>Methods</title> <p>In 2009, we reviewed the Lille Memory Clinic's case database to identify patients suitable for inclusion in four AD clinical trials. An initial selection was made on the basis of four criteria: (i) a diagnosis of AD (with or without white matter lesions [WML]), (ii) age, (iii) mini mental state examination (MMSE) score and (iv) symptomatic treatment of AD (cholinesterase inhibitors/memantine). Next, data on patients fulfilling these criteria were reviewed against all the inclusion/exclusion criteria for four clinical trials performed in 2009 at the Memory Clinic. Reasons for non‐inclusion were analyzed.</p> </sec> <sec id="bcp4423-sec-0003" sec-type="section"> <title>Results</title> <p>Two hundred and five patients were selected according to the four initial criteria. Reasons for subsequently not including some of patients in clinical trials were abnormalities on MRI (56.9%, 88.9% of which were WML), unauthorized medication (37.3%), the lack of a study partner/informant (37.1%), the presence of a non‐authorized disease (24.4%), contraindication to MRI (9%), a change in diagnosis over time (3.9%), visual/auditory impairments (2.9%), alcohol abuse (2%) and an insufficient educational level (1%).</p> </sec> <sec id="bcp4423-sec-0004" sec-type="section"> <title>Conclusion</title> <p>A high proportion of AD patients presented with vascular abnormalities on MRI. This was not unexpected, since the patients were selected from the database and, as shown in epidemiologic studies, cerebrovascular diseases are frequently associated with AD. The presence of a study partner is essential for enabling a patient to participate in clinical trials because of the need to record reliably primary and secondary outcomes.</p> </sec> </abstract>